Publicacións en colaboración con investigadores/as de Erasmus University Medical Center (32)

2024

  1. Clinical networking results in continuous improvement of the outcome of patients with acute promyelocytic leukemia

    Blood, Vol. 144, Núm. 12, pp. 1257-1270

2023

  1. Clinical significance of mitochondrial DNA content in acute promyelocytic leukaemia

    British Journal of Haematology, Vol. 200, Núm. 2, pp. 170-174

2020

  1. Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols

    European Journal of Haematology, Vol. 104, Núm. 3, pp. 162-169

  2. NTAL is associated with treatment outcome, cell proliferation and differentiation in acute promyelocytic leukemia

    Scientific Reports, Vol. 10, Núm. 1

  3. Reduced SLIT2 is associated with increased cell proliferation and arsenic trioxide resistance in acute promyelocytic Leukemia

    Cancers, Vol. 12, Núm. 11, pp. 1-16

2019

  1. An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens

    Leukemia and Lymphoma, Vol. 60, Núm. 4, pp. 1030-1035

  2. Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy

    Leukemia and Lymphoma, Vol. 60, Núm. 5, pp. 1146-1155

  3. Combining gene mutation with gene expression analysis improves outcome prediction in acute promyelocytic leukemia

    Blood, Vol. 134, Núm. 12, pp. 951-959

  4. Management of acute promyelocytic leukemia: Updated recommendations from an expert panel of the European LeukemiaNet

    Blood, Vol. 133, Núm. 15, pp. 1630-1643

2017

  1. Clinical impact of BAALC expression in high-risk acute promyelocytic leukemia

    Blood Advances, Vol. 1, Núm. 21, pp. 1807-1814

  2. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

    Blood, Vol. 129, Núm. 4, pp. 424-447

  3. Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation

    Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380

2015

  1. All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: A matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies

    Annals of Hematology, Vol. 94, Núm. 8, pp. 1347-1356

  2. High Δnp73/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemia

    Blood, Vol. 126, Núm. 20, pp. 2302-2306

2014

  1. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study

    Annals of Hematology, Vol. 93, Núm. 12, pp. 2001-2010

  2. Prognostic impact of KMT2E transcript levels on outcome of patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: An International Consortium on Acute Promyelocytic Leukaemia study

    British Journal of Haematology, Vol. 166, Núm. 4, pp. 540-549

2013

  1. Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL

    Blood, Vol. 121, Núm. 11, pp. 1935-1943

2012

  1. The impact of medical education and networking on the outcome of leukemia treatment in developing countries. The experience of International Consortium on Acute Promyelocytic Leukemia (IC-APL)

    Hematology, Vol. 17, Núm. SUPPL. 1

2011

  1. Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens

    Blood, Vol. 117, Núm. 6, pp. 1799-1805

  2. Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy

    Haematologica, Vol. 96, Núm. 10, pp. 1470-1477